MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: BioPharmaceuticals _ Biotechnology, Genomics, Genetics, Bioinformatics, Biomanufacturing & Personalized Medicine
*Biotechnology: Key Issues
*Key Terms: Biotechnology
Allogeneic
Parents
*Key Terms: Biotechnology
BioTechnology
Children
*Architects: Biotechnology _ Natural Killer (NK) Cells
*Architects: Regenerative Medicine
*Architects: Tissue Engineering _ Stem Cells
*Architects: Tissue Engineering - Musculoskeletal & Orthopedic
*Biotechnology company focused on developing transformative allogeneic, pluripotent stem cells (iPSC)-derived natural killer (NK) and T cell therapies to create products for the treatment of both solid tumor and hematological malignancies
*Immatics’ gamma delta T cell-derived, allogeneic adoptive cell therapy platform, called ACTallo.
*Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
*Joint venture with Teva as an alternative allogeneic therapy for patients with blood cancers such as leukemia and lymphoma
*Key People: Allogene
*Pioneers: Diabetes
*Proprietary platform develops allogeneic, off-the-shelf VSTs (Virus-Specific T Cells) designed to restore immunity in patients with T cell deficiencies.
*The companies will develop multiple allogeneic, or so-called off-the-shelf, TCR-T and CAR-T programs
*Uses gene editing to develop allogeneic, off-the-shelf CAR-T cells for multiple sclerosis and other related autoimmune diseases
2017: High-fidelity genome editing using NextGEN CRISPR (Clo51-dCas9) system for the production of allogeneic CAR-T cells.
2019: Allogene Moves Forward With CAR-T Therapy Pipeline_seekingalpha.com
2019: Allogene Moves Forward With CAR-T Therapy Pipeline_seekingalpha.com
2019: Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy Nasdaq:ALLO
2019: Century Therapeutics Launches With USD 250M Financing for Induced Pluripotent Stem Cell (iPSC) Allogeneic Cell Therapy Platform
2019: Precision Biosciences, Recent IPO: Unique ARCUS Gene Editing And Allogeneic CAR-T Platform_seekingalpha.com
2020: Allogene: Cutting Edge Allogeneic CAR-T Therapy Developer
2020: ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma
2020: Orca Bio Emerges With Nearly $300 Million to Transform Allogeneic Cell Therapy
2021: Allogene Therapeutics: I Am Buying On The Clinical Hold Dip
2021: Caribou Biosciences: Another Gene Editor Hurt By The Allogene Hold
2021: Celularity: Celgene Spin-Off Developing Allogeneic Therapies
2022: Adaptimmune to lay off up to 30% of staff as allogeneic ambitions stunted by cell line change
2022: Allogene Therapeutics (ALLO) Investor presentation - Slideshow_ seekingalpha.com
2022: Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A_ seekingalpha.com
2022: Resilience has formed a strategic collaboration with Be Biopharma to manufacture engineered B Cells to create a new class of autologous and allogeneic cellular medicines.
2024: Allogene links off-the-shelf CAR-T to responses and 3 deaths in phase 1 solid tumor trial
2024: Allogene Therapeutics Receives FDA Regenerative Medicine
2024: Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
2024: Allogene Therapeutics: A Promising Biotech With A Concerning Lag Time Ahead_seekingalpha.com
2024: Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
2024: Allogene Therapeutics: Showing Promise Despite Some Shaky Safety
2024: Allogene Therapeutics: Showing Promise Despite Some Shaky Safety_ seekingalpha.com
2024: In First, Type 1 Diabetic “Cured” by Allogeneic Stem Cell Transplant
2024: TG Therapeutics Receives Clearance from FDA for Phase 1 Trial in Multiple Sclerosis for Allogeneic CAR-T Azer-Cel
2025: Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
2025: Allogene Therapeutics’ ALLO-329 Cleared by FDA for Phase 1 Clinical Trial in Rheumatology Indications
2025: Allogene Therapeutics’ ALLO-329 Received FDA IND Clearance for Autoimmune Disease Trial
2025: Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities
2025: Allogene’s phase 1 lymphoma data show CAR-T could ‘leapfrog’ competition: analysts_
2025: Can Allogene's $37.3M Diagnostic Partnership Transform Lymphoma Treatment Outcomes?
Adicet Bio is a clinical-stage company developing allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer.
Allogene Therapeutics, Inc. (NASDAQ: ALLO)*
Allogeneic Cell Therapy for Blood, Genetic and Immune Diseases
Allogenic bone product
Alphageneron is a clinical stage Cell therapy company with both autologoius NK Cell therapy clinical platform, and allogeneic cell therapy pre-clinical portfolio.
and 3) Compare the incidence of graft failure and cell apoptosis in control and anti-apoptotic gene-expressing, allogeneic corne
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Biopharmaceutical company specialized in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
By using allogeneic and genetically modified gamma-delta (γδ) T cells, IN8bio’s technology addresses certain challenges that immunotherapies face targeting cold, low mutation cancers
Cellectis BioResearch SA (NASDAQ: CLLS)
Celularity is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placenta-derived allogeneic cell therapies, including genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and adherent stromal cells (ASCs), targeting indications across cancer infectious and degenerative diseases.
David Chang, M.D., Ph.D. President, Chief Executive Officer and Co-Founder, Allogene Therapeutics (2023)
FDA _ Regenerative Medicine Advanced Therapy (RMAT)
Finance & Acquisitions: Allogene
Gilead Sciences, Inc. (NASDAQ: GILD)*
Natural Killer (NK) Cells
Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis, through internal discovery and external collaboration, with emphasis on innovative immuno-oncology products.
Organization & Developments: Allogene
Seres Therapeutics, Inc. (Nasdaq: MCRB)*
Smart Immune SAS
Stem Cells
The company is also applying its 3M3 platform to develop truly novel off-the-shelf/allogeneic therapies to address more prevalent tissue defects and a cell-free miRNA exosome therapies for unattainable tissues.
The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting research that applies somatic cell gene editing (SCGE) approaches in animal models or human tissues or organs excluded from clinical use to improve graft survival and outcomes for recipients of allogenic or xenogeneic solid organ or pancreatic islet transplants, or vascularized composite allografts (VCA).
TiGenix is a European cell therapy company with a proprietary validated allogeneic expanded adipose-derived stem cell platform technology for the treatment of autoimmune and inflammatory diseases, and a commercialised product.
Zachary J. Roberts, M.D., Ph.D. Executive vice president, research & development, chief medical officer Allogene Therapeutics (2024)
Jumps
Autologous Cell Therapy (ACT)